The Economics of Heart Failure

Heart Failure Clinics

Volumn 9, Issue 1, 2013, Pages 93-106

  Kazi, Dhruv S ^a   Mark, Daniel B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness; Economics; Heart failure; Quality adjusted life years; Therapies

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; METOPROLOL SUCCINATE; NATRIURETIC PEPTIDE RECEPTOR A; PLACEBO; SPIRONOLACTONE;

CARDIAC RESYNCHRONIZATION THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FOLLOW UP; HEALTH CARE COST; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT VENTRICULAR ASSIST DEVICE; MEDICAL DECISION MAKING; REVIEW; SYSTOLIC HEART FAILURE;

CARDIAC RESYNCHRONIZATION THERAPY; COMPARATIVE EFFECTIVENESS RESEARCH; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MEDICATION THERAPY MANAGEMENT; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT CARE PLANNING; PATIENT SELECTION; QUALITY-ADJUSTED LIFE YEARS;

EID: 84869419314     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.09.005     Document Type: Review

References (71)

1. Health Data 2010: statistics and indicators. 2010. Available at: Accessed December 21, 2010. http://www.oecd.org/document/30/0,3746,en_2649_37407_12968734_1_1_1_37407,00.html.
2. CBO The long-term budget outlook 2007, Congressional Budget Office, Washington DC.
3. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123(4):e18-e209.
4. Neumann P.J., Weinstein M.C. Legislating against use of cost-effectiveness information. N Engl J Med 2010, 363:1495-1497.
5. Smith A. Qualms about QALYs. Lancet 1987, 1:1134-1136.
6. Mark D.B. Economics and cost effectiveness in cardiology. Hurst's the Heart Manual of Cardiology 2011, 2389-2408. McGraw Hill, NewYork. 13th edition. R.A. O'Rourke, V. Fuster, R.W. Alexander (Eds.).
7. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
8. Mueller C., Scholer A., Laule-Kilian K., et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004, 350:647-654.
9. Mueller C., Laule-Kilian K., Schindler C., et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006, 166:1081-1087.
10. Heidenreich P.A., Gubens M.A., Fonarow G.C., et al. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004, 43:1019-1026.
11. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., et al. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 2004, 109:3176-3181.
12. Braunwald E. Expanding indications for beta-blockers in heart failure. N Engl J Med 2001, 344:1711-1712.
13. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
14. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000, 283:1295-1302.
15. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
16. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
17. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
18. Delea T.E., Vera-Llonch M., Richner R.E., et al. Cost effectiveness of carvedilol for heart failure. Am J Cardiol 1999, 83:890-896.
19. Ekman M., Zethraeus N., Jonsson B. Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. Pharmacoeconomics 2001, 19:901-916.
20. Varney S.A. A cost-effectiveness analysis of bisoprolol for heart failure. Eur J Heart Fail 2001, 3:365-371.
21. Kazi D., Deswal A. Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure. Cardiol Clin 2008, 26:1-14. v.
22. Glick H., Cook J., Kinosian B., et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. J Card Fail 1995, 1:371-380.
23. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991, 325:293-302.
24. Lee V.C., Rhew D.C., Dylan M., et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004, 141:693-704.
25. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
26. McMurray J.J., Andersson F.L., Stewart S., et al. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2006, 27:1447-1458.
27. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049-2057.
28. Angus D.C., Linde-Zwirble W.T., Tam S.W., et al. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation 2005, 112:3745-3753.
29. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997, 336:525-533.
30. Uretsky B.F., Young J.B., Shahidi F.E., et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993, 22:955-962.
31. Packer M., Gheorghiade M., Young J.B., et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993, 329:1-7.
32. Ward R.E., Gheorghiade M., Young J.B., et al. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. J Am Coll Cardiol 1995, 26:93-101.
33. Eisenstein E.L., Yusuf S., Bindal V., et al. What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial. J Card Fail 2006, 12:336-342.
34. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
35. Glick H.A., Orzol S.M., Tooley J.F., et al. Economic evaluation of the Randomized Aldactone Evaluation Study (RALES): treatment of patients with severe heart failure. Cardiovasc Drugs Ther 2002, 16:53-59.
36. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
37. Weintraub W.S., Zhang Z., Mahoney E.M., et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2005, 111:1106-1113.
38. Zhang Z., Mahoney E.M., Kolm P., et al. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. Am J Cardiovasc Drugs 2010, 10:55-63.
39. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
40. Juurlink D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543-551.
41. Al-Khatib S.M., Anstrom K.J., Eisenstein E.L., et al. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med 2005, 142:593-600.
42. Mark D.B., Nelson C.L., Anstrom K.J., et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2006, 114:135-142.
43. Sanders G.D., Hlatky M.A., Owens D.K. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005, 353:1471-1480.
44. Hohnloser S.H., Kuck K.H., Dorian P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004, 351:2481-2488.
45. Bigger J.T. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997, 337:1569-1575.
46. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005, 352:1539-1549.
47. Cazeau S., Leclercq C., Lavergne T., et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001, 344:873-880.
48. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004, 350:2140-2150.
49. Auricchio A., Stellbrink C., Sack S., et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002, 39:2026-2033.
50. Abraham W.T., Young J.B., Leon A.R., et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 2004, 110:2864-2868.
51. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002, 346:1845-1853.
52. Young J.B., Abraham W.T., Smith A.L., et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003, 289:2685-2694.
53. Higgins S.L., Hummel J.D., Niazi I.K., et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003, 42:1454-1459.
54. McAlister F.A., Ezekowitz J., Hooton N., et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007, 297:2502-2514.
55. Kazi D., Hlatky M. The cost-effectiveness of cardiac resynchronization therapy. Cardiac resynchronization therapy in heart failure 2009, Lippincott Williams & Wilkins, Philadelphia (London). W. Abraham, R.B. Baliga (Eds.).
56. Calvert M.J., Freemantle N., Yao G., et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J 2005, 26:2681-2688.
57. Nichol G., Kaul P., Huszti E., et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 2004, 141:343-351.
58. Feldman A.M., de Lissovoy G., Bristow M.R., et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005, 46:2311-2321.
59. Yao G., Freemantle N., Calvert M.J., et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007, 28:42-51.
60. Fox M., Mealing S., Anderson R., et al. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Health Technol Assess 2007, Available at:, Accessed January 1, 2008. http://www.ncchta.org/fullmono/mon1147.pdf.
61. Hlatky M.A. Cost effectiveness of cardiac resynchronization therapy. J Am Coll Cardiol 2005, 46:2322-2324.
62. Kazi D., Hlatky M.A. (S)Ticker Shock: The Cost-Effectiveness of Cardiac Resynchronization Therapy With and Without an Implantable Defibrillator in Advanced Symptomatic Heart Failure. Am Coll Card 2008, 51(10):A252.
63. Hunt S.A., Haddad F. The changing face of heart transplantation. J Am Coll Cardiol 2008, 52:587-598.
64. Cope J.T., Kaza A.K., Reade C.C., et al. A cost comparison of heart transplantation versus alternative operations for cardiomyopathy. Ann Thorac Surg 2001, 72:1298-1305.
65. Digiorgi P.L., Reel M.S., Thornton B., et al. Heart transplant and left ventricular assist device costs. J Heart Lung Transplant 2005, 24:200-204.
66. Miller L.W., Nelson K.E., Bostic R.R., et al. Hospital costs for left ventricular assist devices for destination therapy: lower costs for implantation in the post-REMATCH era. J Heart Lung Transplant 2006, 25:778-784.
67. Hernandez A.F., Shea A.M., Milano C.A., et al. Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries. JAMA 2008, 300:2398-2406.
68. Rose E.A., Gelijns A.C., Moskowitz A.J., et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001, 345:1435-1443.
69. Lietz K., Long J.W., Kfoury A.G., et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007, 116:497-505.
70. Wilson S.R., Givertz M.M., Stewart G.C., et al. Ventricular assist devices the challenges of outpatient management. J Am Coll Cardiol 2009, 54:1647-1659.
71. Chan D.C., Heidenreich P.A., Weinstein M.C., et al. Heart failure disease management programs: a cost-effectiveness analysis. Am Heart J 2008, 155:332-338.